Rodent Chronic Toxicology Program for Phase II Pharmaceutical Candidate
The Challenge
A clinical-stage biopharmaceutical company was advancing a first-in-class small molecule oncology compound through development. To support their Investigational New Drug (IND) amendment for Phase II clinical trials, FDA required 26-week chronic toxicity data in a rodent species per ICH M3(R2) guidelines. The compound had a narrow therapeutic index, and preliminary 4-week studies had shown dose-dependent hepatic enzyme elevations that required careful characterization. The client needed a contract laboratory with deep experience in oncology compound evaluation, capable of designing a study that would thoroughly characterize the hepatotoxicity signal while identifying a clear no-observed-adverse-effect level (NOAEL) to support clinical dose selection.
Our Solution
Meramec's toxicology team designed a comprehensive 26-week repeated-dose oral toxicity study in Sprague-Dawley rats per ICH S4 guidelines. The study included 240 animals across 4 dose groups plus vehicle control, with recovery satellite groups. Key design elements included: full toxicokinetic profiling at weeks 1, 13, and 26 to establish exposure-response relationships; enhanced hepatic monitoring with ALT, AST, ALP, GGT, and total bilirubin measured bi-weekly; interim sacrifice at week 13 for early histopathological assessment; liver-specific biomarker panel including miR-122 and GLDH; complete histopathological evaluation of 50+ tissues with peer review by a board-certified veterinary pathologist; and ophthalmological examination at baseline, week 13, and terminal sacrifice.
The Results
The study clearly delineated the dose-response relationship for hepatic effects, identifying a NOAEL at the mid-dose level — approximately 2x the projected human clinical exposure. The enhanced hepatic monitoring revealed that enzyme elevations were adaptive rather than adverse at doses below the NOAEL, an important distinction for clinical risk assessment. Toxicokinetic data confirmed dose-proportional exposure with no accumulation over the 26-week period. The complete data package, including the pathology peer review report, was accepted by FDA without additional information requests. The client initiated Phase II clinical trials on schedule, and the detailed hepatic characterization data informed the clinical monitoring plan that ultimately supported the compound's advancement through Phase III.